序贯与同步放化疗治疗直肠癌的临床分析

The Clinical Analysis of Sequent and Concurrent Chemoradiotherapy for the Rectal Cancer

目的:了解直肠癌使用序贯与同步两种放化疗模式进行治疗的方法及各自的优缺点,总结临床使用序贯与同步放化疗治疗直肠癌的经验。方法:将80例直肠癌(其中Ⅱ期患者为36例,Ⅲ期患者44例)患者随机分为四组,ⅡA和ⅡB组各18例,ⅢA和ⅢB组各22例。A组使用序贯放化疗模式进行治疗,B组使用同步放化疗模式进行治疗。然后比较其两组不同期患者的临床治疗效果。结果:经过分析发现,序贯与同步放化疗模式对Ⅱ期直肠癌患者在疗效上没有显著差异,P>0.05;对于Ⅲ期直肠癌患者,两组放化疗模式对其1年总生存率没有显著差异,P>0.05;但与序贯治疗模式相比,同步治疗模式的1年及3年无进展生存期显著延长,3年总生存率显著提高,P<0.05;同步治疗模式的毒副作用虽然比序贯治疗模式大,但两种放化疗模式相比并没有显著统计差异,P>0.05。结论:对于治疗Ⅲ期直肠癌,同步放化疗模式为更好的治疗模式,其对改善患者的生存质量,延长患者的生存期有重要作用。

Objective： To acquaint the clinical method and its advantage and disadvantage of sequent and concurrent chemoradiotherapy for the rectal cancer,and sum up the clinical experiences of it.Method： 80 cases with rectal cancer（36 cases were in stageⅡ,and 44 cases were in stageⅢ） were randomly divided into ⅡA group（18 cases）,ⅡB（18 cases）,ⅢA（22 cases）,ⅢB（22 cases）.The A group was given the treatment of sequent and chemoradiotherapy pattern,and the B group was given the treatment of concurrent chemoradiotherapy pattern,then compared effectiveness of the different stage patent.Result： The two patterns to Ⅱ stage rectal cancer had no significant differences,and its adverse effects has no significant（P〉0.05）,but the 1 and 3 years disease-free survival global rate had significant differences（P〈0.05）.Conclusion： The Ⅲ stage patent for concurrent chemoradiotherapy is the better treatment,It’s important to improve the living quality and extend the alive stage.